Your session is about to expire
← Back to Search
LTP001 for Pulmonary Arterial Hypertension
Study Summary
This trial tests if a drug (LTP001) is safe and effective for treating pulmonary arterial hypertension (PAH).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a specific type of high blood pressure in the lungs related to genetics, heart defects, or certain drug use.My heart test shows high pressure in the lungs' blood vessels.You have limitations in physical activity and may experience some discomfort with normal activity.I do not have any health issues that would stop me from doing physical activities required in the study.I can walk between 150 and 550 meters in 6 minutes.My lung function tests show I have severe breathing issues.My heart's pressure readings meet specific criteria from a recent test.I've been on a stable heart or lung treatment for at least 6 weeks.I do not have significant heart disease affecting the left side of my heart.I have pulmonary hypertension but not from the heart's left side.
- Group 1: LTP001
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still enrollment opportunities available for individuals interested in this research?
"Affirmative, clinicaltrials.gov lists this trial as currently accepting patients. Initially posted on June 30th 2022 and last revised April 17th 2023; the research is now enrolling 44 individuals across 12 locations."
What health risks could be incurred by taking LTP001?
"Our team at Power assigned LTP001 a rating of 2 on the safety scale, as there is limited data indicating its efficacy yet more substantial evidence suggesting that it may be safe."
Is this research endeavor including participants aged seventy and older?
"This trial is open to participants aged between 18 and 75. For those below the age of consent, there are 53 trials available while 664 exist for seniors above 65 years old."
Am I eligible to take part in this clinical experiment?
"To successfully be accepted for this trial, aspirants must suffer from pulmonary arterial hypertension and fall into the age bracket of 18 to 75. The total number of participants being sought is 44."
What is the maximum amount of participants who can enroll in this trial?
"Affirmative. The details on clinicaltrials.gov suggest that this study is still welcoming participants, having originally been posted at the end of June 2022 and recently updated in mid-April 2023. Forty four patients need to be enrolled from 12 sites."
In what capacity are hospitals participating in this research initiative?
"As of now, recruitment for this study is taking place in 12 different medical centres spread across Caba, Santander and Barcelona. To minimize the need to travel far distances, it may be beneficial to choose a clinic close-by when considering enrollment into this trial."
Share this study with friends
Copy Link
Messenger